New Cholesterol Pill Slashes Levels by 60% at $10 Per Day

Most adults walk around with cholesterol levels above 100, a ticking time bomb for heart disease and stroke. A newly approved pill called enlicitide can drop those numbers to 50 or lower, giving patients protection statins alone can't deliver.

The FDA just greenlit this once-daily medication from pharmaceutical giant Merck, marking a major milestone in the fight against heart disease. Clinical trials showed enlicitide lowered cholesterol by up to 60 percent over six months in adults with or at risk of cardiovascular disease.

What makes this approval special isn't just the effectiveness. Injectable drugs that work the same way have existed for about a decade, but they carry hefty price tags that put them out of reach for many patients. Enlicitide will sell under the brand name Lipfendra for $315 per month, making it far more accessible.

The drug works by blocking PCSK9, a protein your liver produces that actually slows down your body's natural cholesterol cleanup system. By inhibiting this protein, enlicitide lets your body flush out the bad cholesterol more efficiently.

Eric Topol, a cardiologist and director of the Scripps Research Translational Institute, called the approval good news. Patients now have an FDA-approved pill that achieves cholesterol reduction comparable to those expensive injectable medications.

The timing couldn't be better. The American Heart Association and American College of Cardiology released updated guidelines in March recommending patients at risk of heart attack or stroke aim for LDL levels below 70. For high-risk individuals, the target drops to below 55.

The Ripple Effect spreads beyond just the patients who'll take this medication. When breakthrough treatments become affordable, they set a new standard for what's possible in healthcare. More people getting their cholesterol under control means fewer heart attacks, fewer strokes, and more families that don't have to face preventable tragedy.

Clinical trial data shows enlicitide has side effects similar to a placebo, meaning most people tolerate it well. Merck is now conducting trials to confirm whether this cholesterol reduction translates directly into preventing heart attacks and strokes, though overwhelming evidence already links high LDL cholesterol to increased cardiovascular risk.

This approval represents decades of research paying off in a form people can actually use and afford.